Evidence map›Paper›PMID 35086627›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2022

Early mortality during rifampicin-resistant TB treatment.

E Mohr-Holland, J Daniels, A Reuter, C A Rodriguez, C Mitnick, Y Kock, V Cox, J Furin, H Cox

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

E Mohr-HollandKhayelitsha Project, Médecins Sans Frontières (MSF), Cape Town, South Africa, Southern Africa Medical Unit, MSF, Cape Town, South Africa.
J DanielsKhayelitsha Project, Médecins Sans Frontières (MSF), Cape Town, South Africa.
A ReuterKhayelitsha Project, Médecins Sans Frontières (MSF), Cape Town, South Africa.
C A RodriguezDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
C MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Y KockNational Department of Health, Pretoria, South Africa.
V CoxCenter for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
J FurinDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
H CoxDivision of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa, Institute for Infectious Disease and Molecular Medicine and Wellcome Centre for Infectious Disease Research in Africa, University of Cape Town, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsDiarylquinolinesFemaleHumansMicrobial Sensitivity TestsRetrospective StudiesRifampinAntitubercular AgentsDiarylquinolinesRifampin

Identifiers

PMID35086627
PMCPMC8802559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.